-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tislelizumab in Ureter Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tislelizumab in Ureter Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tislelizumab in Ureter Cancer Drug Details: Tislelizumab (Baizean, Tevimbra, Tizveni) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Typhella in Typhoid Fever
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Typhella in Typhoid Fever report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Typhella in Typhoid Fever Drug Details: Typhella is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Salmonella Immunotherapy in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Salmonella Immunotherapy in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Salmonella Immunotherapy in Non...
-
Product Insights
NewPlague – Drugs In Development, 2024
Empower your strategies with our Plague – Drugs In Development, 2024 report and make more profitable business decisions. Plague is an infection caused by the bacterium Yersinia pestis. The organism is transmitted to humans who are bitten by fleas that have fed on infected rodents, or when human handle infected animals. Symptoms include headache, fatigue or malaise, muscle aches, fever and chills, abdominal pain, diarrhea and vomiting, shock, and bleeding from the mouth, nose, ectum, or under the skin. Treatment includes...
-
Product Insights
NewTraveler’s Diarrhea – Drugs In Development, 2024
Empower your strategies with our Traveler's Diarrhea – Drugs In Development, 2024 report and make more profitable business decisions. Traveler's diarrhea occurs within 10 days of travel to an area with poor public hygiene. The most common illness in travelers, it is caused by drinking water or eating food that contains bacteria, viruses, or parasites. Most traveler's diarrhea is from bacteria. It often goes away in a few days. Often, the only treatment is fluid replacement. The Traveler's Diarrhea drugs in...
-
Product Insights
NewTyphoid Fever – Drugs In Development, 2024
Empower your strategies with our Typhoid Fever – Drugs In Development, 2024 report and make more profitable business decisions. Typhoid fever is an infection that causes diarrhea and a rash. It is most commonly due to a type of bacterium called Salmonella typhi. Symptoms include abdominal tenderness, agitation, chills, delirium, hallucinations, severe fatigue, and weakness. Treatment includes antibiotics and supportive therapy. The Typhoid Fever drugs in development market research report provide comprehensive information on the therapeutics under development for Typhoid Fever,...
-
Product Insights
NewDiarrhea – Drugs In Development, 2024
Empower your strategies with our Diarrhea – Drugs In Development, 2024 report and make more profitable business decisions. Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include nausea, abdominal pain, cramping, bloating, dehydration, fever, bloody stools, frequent urge to evacuate the bowels and incontinence. Treatment includes medication and healthy lifestyle. The Diarrhea drugs in development market research report...
-
Product Insights
NewNon Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) – Drugs In Development, 2024
Empower your strategies with our Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) – Drugs In Development, 2024 report and make more profitable business decisions. Non-Muscle-Invasive Bladder Cancer (NMIBC), also referred to as superficial bladder cancer, is a type of bladder cancer that is confined to the innermost lining of the bladder. Unlike muscle-invasive bladder cancer, which penetrates the muscle layer of the bladder wall, NMIBC stays within the lining and does not invade deeper layers or surrounding tissues. NMIBC...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Salmonella Immunotherapy in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Salmonella Immunotherapy in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Drug Details: The...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KSP-1007 in Bacterial Infections
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KSP-1007 in Bacterial Infections Drug Details: KSP-1007 is under development for the treatment of...